Press Release

Osteoporosis Drugs Market to Grow with a CAGR of 5.73% through 2028

Increasing incidences of osteoporosis and the growing investments in research & development by biopharmaceutical companies is expected to drive the Global Osteoporosis Drugs growth in the forecast period, 2024-2028.

 

According to TechSci Research report, “Osteoporosis Drugs Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Osteoporosis Drugs stood at USD 16.09 billion in 2022 and is anticipated to grow with a CAGR of 5.73% in the forecast period, 2024-2028. The significant factor contributing to the growth of the osteoporosis drugs market is the increasing prevalence of osteoporosis. Moreover, the market is further propelled by the rising geriatric population worldwide and the adoption of sedentary lifestyles.

 

Additionally, the increasing number of patent expirations is putting therapeutic pressure on the utilization of generic forms of existing drugs, which is anticipated to further boost the market for generic osteoporosis drugs throughout the forecast period. These combined factors are expected to present significant growth opportunities in the near future. Furthermore, an expansion of awareness programs aimed at educating patients and doctors about osteoporosis treatment is projected to enhance the development prospects of the osteoporosis market during the forecast period.

           

 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Osteoporosis Drugs Market.”

 

 

The osteoporosis drug industry is poised to experience significant growth due to the increasing elderly population and the prevalence of target diseases such as osteoporosis. The global occurrence of osteoporosis, coupled with the high demand for drugs in prevention and treatment, is driving the expansion of the osteoporosis drug market in recent years. The industry is projected to grow at a higher CAGR over the next seven years, presenting numerous opportunities for market players to invest in research and development of osteoporosis drugs.

 

Osteoporosis is a leading cause of reduced bone density, leading to pain even from minor injuries or trauma. Each year, as many as nine million people worldwide are reported to suffer from osteoporosis, resulting in frequent osteoporotic conditions occurring every three seconds. Menopausal women are particularly vulnerable, with one out of three women over the age of fifty experiencing an osteoporotic fracture. These factors contribute to the growth of the osteoporosis drugs market, creating lucrative opportunities for market players in recent years. The substantial increase in the elderly population in both developed and developing economies globally is driving the demand for osteoporosis drugs.

 

The availability of disease management guidelines serves as a significant catalyst for the growth of the osteoporosis drug market. It is imperative for physicians to adhere to evidence-based recommendations for their patients, given the escalating global incidences of osteoporosis. These guidelines, developed based on scientific evidence and taking into account patient needs and ongoing therapies, are expected to foster the growth of the osteoporosis drugs market during the forecast period.

 

The rise in healthcare costs worldwide, coupled with increasing disease prevalence and government as well as non-government initiatives, necessitates the improvement of healthcare infrastructure and accessibility to treatment. Enhanced healthcare awareness, focused efforts on women's health maintenance, and the introduction of new products by manufacturers are driving factors contributing to an expanding market share.

 

Moreover, the growth of the osteoporosis drug industry is propelled by the expanding healthcare sectors in emerging economies such as China, India, Brazil, and South Africa. To capitalize on new growth opportunities, increased investment in research and development is imperative. The rapidly growing geriatric population, high patient volumes, and rising public awareness are key factors that demand improvements in healthcare industries in these nations.

 

The significant global burden of osteoporosis is projected to offer substantial growth opportunities in the coming years. This is expected to drive the urgent need for the development of new molecules for treatment. Consequently, the anticipated launch of several pipeline drugs for osteoporosis treatment is expected to contribute to future growth. Currently, there are 26 medications in Phase-I & -II and Phase IIb and III, indicating a growing research platform. This can be attributed to collaborative research activities initiated by major pharmaceutical companies to enhance their competitive position in the branded medication market.

 

Consequently, governments in these economies are augmenting their investments in healthcare facilities and infrastructure. Regional expansion, new product development, industry collaboration, talent acquisition, and mergers and acquisitions are additional strategies employed to gain a competitive advantage in the global market. The substantial investment in this sector, driven by a multitude of coronary stent applications, is expected to provide opportunities for market expansion.

 

The Global Osteoporosis Drugs is segmented into drug type, route of administration, application, distribution channel, regional distribution, and company.

Based on drug type, the global osteoporosis drug market is categorized into different drug classes that have contributed to the market's growth. Bisphosphonates have accounted for the majority of market shares, prompting major players to increase investments in research and development of innovative novel bisphosphonates. The market expansion is also driven by the widespread use of bisphosphonates in osteoporosis treatment. During the forecast period, the rank ligand inhibitors market is expected to experience the fastest rate of expansion, given their role in managing bone transformation by acting as a chemoattractant to the bone for tumor cells that accelerate their RANK receptor.

 

Based on region, North America segment is expected to grow during the forecast period.  North America holds a dominant position in the osteoporosis drugs market and is expected to maintain this trend throughout the forecast period. The region's strong market presence is attributed to key players, a high prevalence of osteoporosis patients, well-established healthcare infrastructure, and the availability of branded drugs.

 

Among the countries in North America, the United States has the largest market share. This is primarily due to factors such as a growing adult population, an increasing number of patients, and collaborative efforts by large companies to enhance their capabilities and uphold higher medical standards. According to the National Osteoporosis Foundation (NOF), the number of diagnosed osteoporosis cases in the United States has exceeded 10 million since 2020, with a higher incidence among menopausal women. Consequently, the rising incidence of osteoporosis in women during menopause is expected to significantly contribute to the regional osteoporosis drug market's growth.

 

Additionally, the increasing demand in North America stems from collaborative research programs by major health organizations and companies, as well as the development of new products aiming to improve alternative therapies in the current market landscape. For instance, in 2019, Amgen received approval from the US FDA for its Evenity (romosozumab-aqqg), a treatment for osteoporosis in postmenopausal women at high risk of fractures. This approval presents new growth opportunities for the regional market. The aforementioned factors highlight the professional tone while retaining the original meaning of the text.

 

Major companies operating in Global Osteoporosis Drugs are:

  • Eli Lilly and Company
  • Pfizer Inc.
  • F. Hoffmann-La Roche
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc.
  • Novartis International AG
  • Merck & Co. Inc.
  • Amgen Inc.
  • Radius Health Inc.
  • Actavis PLC

 

Download Free Sample Report

Customers can also request for 10% free customization on this report.

 

“The increasing prevalence of osteoporosis, attributed to sedentary lifestyles, excessive alcohol consumption, and rising tobacco use, is driving market growth. Additionally, the growing number of individuals with celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma, and rheumatoid arthritis is further fueling market expansion. Furthermore, age-related bone mass loss increases the risk of developing osteoporosis among the elderly, contributing to the demand for osteoporosis drugs. Moreover, regulatory authorities are actively developing novel therapeutics, including those approved by the US Food and Drug Administration (FDA) for postmenopausal women at high risk of fractures or intolerant to other therapies. Additionally, the market is expected to witness growth with the introduction of a wide range of drugs in late-stage clinical trials.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

 

Osteoporosis Drugs Segmented By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types), By Route of Administration (Oral, Injectables, Others), By Application (Primary Osteoporosis and Secondary Osteoporosis), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Osteoporosis Drugs and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Osteoporosis Drugs.

 

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com

Relevant News